'Bionanotechnology from Theory to Practice' is a short online, course providing an interdisciplinary and up-to-date overview of the rapidly developing area of bionanotechnology
Page URL: https://www.bionews.org.uk/page_90848

New embryo test could detect thousands of hereditary disorders

27 October 2008
Appeared in BioNews 481

UK scientists have developed a new screening technique that could allow prospective parents to test their IVF embryos for any known genetic disease. The test, dubbed 'a genetic MoT', would cost just £1500 and could be available by next year pending licensing by the Human Fertilisation and Embryology Authority (HFEA).

There are approximately 15,000 known genetic disorders and currently only two per cent of these can be tested for. The HFEA permits couples to use these tests to screen their IVF embryos prior to implantation in order to avoid having children with debilitating hereditary conditions. Now, researchers at the Bridge Centre in London have developed a new technology called 'embryo' that they say will be able to detect any genetic disease using a single test.

Conventional genetic screening techniques are limited to searching for the presence of specific genes or gene combinations. Karyomapping, by contrast, examines the embryo's whole complement of DNA and compares it to those of the parents, grandparents and any siblings. By tracking 300,000 specific genetic markers through the generations, the family's genetic history can be mapped out and the presence of any genetic regions associated with familial hereditary disorders in the embryo's DNA can be flagged up.

Professor Alan Handyside, who led the research team, told BBC News Online: 'the current tests can only identify a small number of defects. One of the main things for patients is that, quite often, there isn't a test for their particular condition. This is a single test - a universal method'. Karyomapping has been successfully used to screen embryos at the Hammersmith Hospital, London, but the technology is still in the early stages and further evidence will be needed before the HFEA grants a licence for it to be made commercially available. Prof. Handyside said: 'We are still validating it, but it is going to be a revolution if it works out. It makes genetic screening very much more straightforward'.

Theoretically, the technique could be further applied to determining a predisposition towards many more complicated disorders with genetic elements, such as heart disease, diabetes, breast cancer and Alzheimer's, or even to detecting other genetic traits such as eye colour. This has led to concern that it could be used for the selection of 'designer babies'. The researchers, however, refuted this, saying: 'When you start looking for more than two or three traits, you've just got no chance of getting a match. You'd need thousands of embryos, and we don't have a practical way of making thousands of embryos'. Furthermore, the HFEA will have the authority to specify exactly what the technique can or cannot be used for.

SOURCES & REFERENCES
Finding the faulty gene: Embryology test that could kill off inherited illnesses
The Times |  24 October 2008
Genetic MoT will detect disease in unborn child
The Times |  24 October 2008
Groundbreaking test will screen embryos for genetic disorders
The Daily Telegraph |  24 October 2008
'One-stop' embryo test unveiled
BBC News Online |  24 October 2008
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
13 April 2015 - by Dr Rachel Montgomery 
The first baby in Europe has been born following a new IVF-based technique developed to prevent the inheritance of genetic disorders...
12 August 2008 - by Joy Delhanty, Karen Fordham, Joyce Harper, Sioban SenGupta and Paul Serhal 
Inherited cancer predisposition is rare, however preimplantation genetic diagnosis (PGD) for this group of disorders is steadily increasing. Unlike other common indications for PGD such as cystic fibrosis, PGD for cancer predisposition avoids the inheritance of a very high susceptibility to developing cancer rather than inheritance of the disease itself...
21 July 2008 - by Alison Cranage 
The use of DNA chip (microarray) technology in embryo screening is to be investigated by an ethics task force from the European Society of Human Reproduction and Embryology (ESHRE). The technology has the potential to screen IVF embryos, in order to improve fertility treatment success rates. In...
7 July 2008 - by Ailsa Stevens 
BioNews reporting from ESHRE conference, Barcelona:By Ailsa Taylor: Amidst current debate about the implications of allowing couples to select embryos free from conditions with later onset, incomplete penetrance and (limited) treatment options, ethicists have recommended that parents undergoing pre-implantation genetic diagnosis (PGD) should, in certain circumstances, be allowed to...
16 June 2008 - by Alison Cranage 
The British Fertility Society (BFS) has issued new guidelines for the use of pre-implantation genetic screening (PGS) in patients undergoing fertility treatment. The new guidelines, published in the journal Human Fertility, state that there is no evidence that PGS improves pregnancy rates or decreases miscarriage rates for...
9 June 2008 - by Antony Starza-Allen 
A British couple has successfully used pre-implantation genetic diagnosis (PGD) funded by the NHS to create a baby free from neurofibromatosis type 1, a potentially serious genetic condition. This is reported to be the first time PGD has been used for this condition. The baby's father, Peter...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.